Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the selective destruction of insulin-producing beta cells in the pancreatic islets. The immune system mistakenly identifies these cells as foreign, launching a coordinated attack driven by autoreactive T cells, B cells, and innate immune effectors. While conventional management relies on exogenous insulin replacement, there is an urgent need for disease-modifying therapies that can re‑establish immune tolerance and preserve residual beta cell function. Over the past decade, a specialized subset of B lymphocytes known as regulatory B cells (Bregs) has emerged as a critical player in restraining autoimmune inflammation. This article provides a comprehensive review of Breg biology, their role in modulating T1D, and the therapeutic promise they hold.

What Are Regulatory B Cells?

Regulatory B cells are a heterogeneous population of B lymphocytes that exert suppressive functions via the secretion of anti‑inflammatory cytokines—most notably interleukin‑10 (IL‑10)—as well as through cell‑contact‑dependent mechanisms. Unlike conventional B cells that produce antibodies and promote humoral immunity, Bregs actively dampen immune responses and help maintain peripheral tolerance. They have been identified in both mice and humans, typically defined by surface markers such as CD19+CD24hiCD38hi in humans (transitional B cells) and CD1dhiCD5+ in mice. Additional subsets include plasmablast‑derived Bregs and IL‑10‑producing B10 cells.

The key effector molecule of Bregs is IL‑10. This cytokine downregulates the expression of major histocompatibility complex class II and co‑stimulatory molecules on antigen‑presenting cells, reduces the production of pro‑inflammatory cytokines such as tumor necrosis factor‑α (TNF‑α) and interferon‑γ (IFN‑γ), and directly suppresses the activation and proliferation of pathogenic T cells. Bregs also produce transforming growth factor‑β (TGF‑β) and can induce the generation of regulatory T cells (Tregs), further amplifying the suppressive network.

Bregs in Autoimmune Regulation

In the context of autoimmunity, Bregs serve as a natural brake on inflammatory cascades. Several animal models of autoimmune diseases—including rheumatoid arthritis, multiple sclerosis, and lupus—have demonstrated that depletion of Bregs exacerbates disease, whereas adoptive transfer of Bregs ameliorates pathology. The IL‑10‑dependent suppression of autoreactive T cells and the modulation of dendritic cell function are central to this benefit. Importantly, Breg numbers and functional capacity are often impaired in autoimmune conditions, suggesting that Breg insufficiency contributes to breakdown of self‑tolerance.

Research also highlights the plasticity of Bregs: they can be induced from naïve or memory B cells in response to specific microenvironments, including chronic antigen stimulation, toll‑like receptor (TLR) activation, and exposure to cytokines such as IL‑21 and IL‑4. This inducibility opens the door to therapeutic strategies that boost Breg numbers or potency in patients with autoimmune diseases.

Regulatory B Cells in Type 1 Diabetes

A growing body of evidence implicates Bregs in the pathogenesis and potential treatment of T1D. In non‑obese diabetic (NOD) mice, a well‑established model of human T1D, Bregs are reduced in number and function during the pre‑diabetic phase. Transfer of IL‑10‑producing B cells from young NOD mice into prediabetic recipients significantly delays diabetes onset. Conversely, B‑cell‑specific deletion of IL‑10 accelerates disease, underscoring the protective role of Breg‑derived IL‑10.

In humans, studies have shown that individuals with T1D exhibit lower frequencies of CD19+CD24hiCD38hi Bregs in peripheral blood compared to healthy controls. Moreover, the remaining Bregs produce less IL‑10 upon stimulation. This functional deficit correlates with markers of beta cell autoimmunity and loss of C‑peptide secretion. Interestingly, residual beta cell function appears to be positively associated with Breg frequency, suggesting that maintaining or restoring Breg activity could help preserve endogenous insulin production.

Mechanisms of Breg Suppression in T1D

Bregs employ multiple mechanisms to subdue autoreactive responses in T1D:

  • IL‑10 secretion: The primary suppressive axis. IL‑10 inhibits the activation of diabetogenic CD4+ and CD8+ T cells, reduces the production of pro‑inflammatory cytokines (e.g., IL‑1β, IFN‑γ), and impairs antigen presentation by dendritic cells and macrophages.
  • Cell‑contact‑dependent suppression: Bregs can directly engage T cells through surface molecules such as CD80/CD86 (via CTLA‑4 ligation) and PD‑L1, delivering inhibitory signals that limit T cell proliferation and effector function.
  • Induction of regulatory T cells: Bregs promote the differentiation and expansion of Foxp3+ Tregs, both through IL‑10 and TGF‑β secretion and through co‑stimulatory interactions. The Treg compartment is also suboptimal in T1D, so boosting it via Bregs represents a synergistic therapeutic goal.
  • Modulation of innate immunity: Bregs suppress the activation of dendritic cells and shift macrophages toward an anti‑inflammatory M2 phenotype, further containing the inflammatory milieu within the pancreatic islets.

Clinical Implications and Therapeutic Strategies

The recognized role of Bregs in T1D has inspired multiple therapeutic avenues aimed at enhancing their frequency or function. These approaches are designed to restore immune tolerance without broadly immunosuppressing the patient.

Breg Expansion In Vivo

Several agents have been shown to expand Breg populations in preclinical models. For example, low‑dose interleukin‑2 (IL‑2) therapy, which predominantly expands Tregs, also modestly increases Bregs. More specific approaches include administration of CD40‑ligand antibodies or CpG oligonucleotides (TLR9 agonists) that preferentially activate IL‑10‑producing B cells. In NOD mice, treatment with anti‑CD40 or with certain B‑cell antigens (e.g., proinsulin coupled to an immunogenic carrier) has delayed diabetes by expanding and activating Bregs.

Another promising strategy involves the use of antigen‑specific immunotherapy. Coupling diabetes‑relevant antigens (insulin, GAD65, ZnT8) with molecules that target the B‑cell receptor on potentially regulatory B cells could selectively expand the IL‑10‑producing pool. Preclinical studies have used fusion proteins of antigen with IL‑10 or with apoptotic cell membranes to induce Bregs that suppress T cell responses in an antigen‑specific manner.

Adoptive Breg Transfer

Adoptive transfer of ex vivo‑expanded autologous Bregs represents a more direct cell therapy. Protocols have been developed to generate large numbers of IL‑10‑producing B cells from human blood using a cocktail of CD40L, CpG, and cytokines. In mouse models, transferred Bregs home to lymphoid organs and the pancreas, where they suppress effector T cells and protect beta cells. A phase I clinical trial (NCT03710924) has evaluated intravenous infusion of autologous Bregs in patients with established T1D, with preliminary results indicating safety and potential preservation of C‑peptide levels. Larger placebo‑controlled trials are being planned.

Combination Therapies

Because the immune dysregulation in T1D involves multiple cell types, combining Breg‑based interventions with other immunomodulatory agents may yield superior outcomes. For example, pairing Breg therapy with low‑dose IL‑2 (to boost Tregs) or with checkpoint inhibitors (to block exhaustion of Tregs) could create a robust tolerogenic milieu. Similarly, co‑administration of antigen‑specific immunotherapy with systemic Breg expansion might induce durable tolerance, much like allergen‑specific immunotherapy for allergies.

Current Research and Clinical Trials

The translation of Breg science from bench to bedside is accelerating. Several early‑phase trials are either recruiting or underway:

  • NCT03710924: A first‑in‑human trial of ex vivo‑expanded autologous Bregs in T1D patients (completed; results pending publication).
  • NCT04573790: A study assessing the safety of low‑dose IL‑2 combined with a GAD‑alum vaccine to induce Tregs and Bregs in recent‑onset T1D.
  • Preclinical studies: Multiple groups are refining Breg expansion protocols, identifying optimal Breg subsets (e.g., plasmablast‑derived Bregs vs. transitional Bregs), and exploring gene‑editing approaches to enhance Breg stability and IL‑10 production.

Challenges remain, including the heterogeneity of Bregs, lack of a single defining marker, and the risk that adoptively transferred Bregs might convert into pro‑inflammatory B cells (so‑called Beff cells) under certain conditions. Rigorous manufacturing and quality control are essential to ensure product consistency and regulatory approval.

Future Directions

To realize the full potential of Breg‑based therapies for T1D, the field must address several key questions:

  • Identification of definitive Breg markers: A canonical surface signature that reliably distinguishes Bregs from effector B cells would facilitate both isolation and monitoring.
  • Understanding Breg biology in the target organ: Most studies rely on peripheral blood; the phenotype and function of Bregs within the pancreatic islets and draining lymph nodes remain poorly characterized.
  • Biomarkers of Breg activity: Serum IL‑10 levels or Breg‑specific gene expression signatures could serve as pharmacodynamic biomarkers to guide dosing and predict therapeutic response.
  • Personalized medicine: Given the heterogeneity of T1D, strategies that match the type of Breg therapy to the patient’s immune profile (e.g., those with severe IL‑10 deficiency vs. those with low Breg numbers) may improve outcomes.
  • Long‑term durability: It is unknown whether a single course of Breg transfer can establish lasting tolerance or if periodic boosters will be required.

Conclusion

Regulatory B cells represent a promising yet underutilized tool in the fight against type 1 diabetes. Their ability to suppress autoreactive T cells, induce regulatory networks, and modulate the immune microenvironment positions them as a natural candidate for tolerance‑restoring therapies. Preclinical evidence is robust, and early clinical trials are beginning to yield safety and efficacy data. As our understanding deepens, Breg‑based interventions—whether through expansion in vivo, adoptive transfer, or combination regimens—may one day supplement or even supplant insulin therapy, offering a disease‑modifying option for individuals living with T1D. Continued investment in basic and translational research will be essential to unlock the full therapeutic potential of these remarkable cells.